Lumigan (Bimatoprost) Eye Drops for Glaucoma
Lumigan is an ophthalmic prostaglandin analogue containing bimatoprost. It is used in adults for ocular hypertension and chronic open-angle glaucoma, with once-daily evening dosing and significant reductions in intraocular pressure.
- Active ingredients
- Bimatoprost
- Manufacturer
- AbbVie / Allergan
- Dosage forms
- ophthalmic solution
- Available dosages
- 0.01%, 0.03%
- Category
- Eye Care and Ophthalmic Treatments
What is it?
Lumigan is the original brand of bimatoprost ophthalmic solution, marketed by AbbVie (originally Allergan). It was approved by the United States Food and Drug Administration in 2001 and is supplied as 0.01% and 0.03% ophthalmic solutions. Lumigan is dispensed only on prescription. A separate bimatoprost product, Latisse, is approved for hypotrichosis of the eyelashes. Multiple authorised generics of bimatoprost ophthalmic solution are now available.
Active ingredients
Each milliliter of Lumigan ophthalmic solution contains bimatoprost as the sole active ingredient at 0.1mg (0.01%) or 0.3mg (0.03%). Bimatoprost is a synthetic structural analogue of prostamide F2-alpha that increases aqueous humour outflow through both the trabecular meshwork and the uveoscleral pathway.
Forms and dosages
Lumigan is administered as one drop in the affected eye(s) once daily, ideally in the evening. According to the prescribing information, more frequent dosing reduces rather than enhances the pressure-lowering effect. Multiple ophthalmic medications should be separated by at least 5 minutes. Contact lenses should be removed before administration and may be reinserted 15 minutes later.
Indications
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. According to international guidelines, prostaglandin analogues such as bimatoprost are typically first-line therapy for newly diagnosed glaucoma because of their efficacy, once-daily dosing and favourable systemic safety profile. Combination with other agents is considered when the target intraocular pressure is not achieved with monotherapy.
How it works
Bimatoprost is a prostamide analogue that increases aqueous humour outflow through both the trabecular meshwork and the uveoscleral pathway, lowering intraocular pressure. Unlike pure prostaglandin F2-alpha analogues such as latanoprost, bimatoprost may act on prostamide receptors in addition to FP receptors. The intraocular pressure-lowering effect persists for at least 24 hours, supporting once-daily dosing.
Frequently asked questions
How is Lumigan different from Xalatan? ▾
Both are prostaglandin-class glaucoma agents. Lumigan contains bimatoprost (a prostamide analogue), while Xalatan contains latanoprost (a true prostaglandin F2-alpha analogue). Clinical efficacy is broadly comparable, with bimatoprost producing slightly greater pressure reduction in some studies but more pronounced conjunctival hyperaemia. According to international guidelines, the choice depends on individual response and tolerability, with the prescriber making the final decision.
Why does Lumigan cause iris colour changes? ▾
Prostaglandin analogues including bimatoprost stimulate melanogenesis in iris melanocytes, leading to gradual increases in brown pigmentation. The change is most noticeable in patients with mixed-colour irises (blue-brown, green-brown, hazel) and is permanent. According to the prescribing information, patients should be informed of this possibility before initiating therapy. The cosmetic change does not affect ocular function or glaucoma control.
Can Lumigan grow eyelashes? ▾
Lumigan can stimulate growth and darkening of the eyelashes as an adverse effect when used for glaucoma. A separate bimatoprost product (Latisse) is approved in some markets specifically for hypotrichosis of the eyelashes. According to the prescribing information for Lumigan, eyelash changes are usually reversible after discontinuation, while iris pigmentation changes are permanent. The two products differ in formulation and indication.
When should Lumigan be applied? ▾
Lumigan is applied as one drop in the affected eye(s) once daily, ideally in the evening. According to the prescribing information, this timing produces optimal control of diurnal intraocular pressure variation. More frequent dosing reduces rather than enhances the pressure-lowering effect. If a dose is missed, the next dose should be applied at the usual time without doubling.
What are the main contraindications for Lumigan? ▾
Lumigan is contraindicated in known hypersensitivity to bimatoprost or its excipients. Caution is required in active intraocular inflammation, in aphakic or pseudophakic patients with disrupted posterior lens capsule (risk of macular oedema), and in pregnancy and breastfeeding. According to the prescribing information, the medical history must be reviewed by a clinician before any prescription, particularly in patients with a history of uveitis.
Related medications
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.